J.P. Morgan, MannKind's plans to partner inhaled insulin are on hold until the Food & Drug Administration completes its review of the pending application for Afresa. And Wall Street analysts have some advice for investors who... [read full story]
|
RELATED
|
|
third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present -- its lead...
Finance, Banking & Insurance, Investing & Markets, Pharmaceuticals, Metabolic Problems, Cancer by Body Location, Medicines & Remedies, Stock Capital Issues, Health Care, Cancers, Diabetes, Patients, Financial Markets, Investing, Stock Price Changes, Lung Cancer, Anti-diabetic Drugs, Stock Markets, Eli Lilly, Sanofi, J.P. Morgan, Aventis, Novo-Nordisk, Pfizer
